Hydar El Jamaly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hydar El Jamaly has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Guy D. Eslick
Faculty of Medicine and Health, Specialty of Child and Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia
2 shared publications Martin Weltman
Department of Gastroenterology and Hepatology Nepean Hospital Penrith New South Wales Australia
2 shared publications- Martin Weltman
Nepean Hospital Penrith New South Wales Australia
2 shared publications Guy D Eslick
The Centre for Digestive Health and Neurogastroenterology, Hunter Medical Research Institute, The University of Newcastle, Newcastle, Australia
1 shared publicationGuy D. Eslick
The NHMRC Centre for Research Excellence for Digestive Health Hunter Medical Research Institute, The University of Newcastle Newcastle New South Wales Australia
1 shared publication
Latest Publications
- 17 August 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 56 (7) , 1104-1118
Meta‐analysis: hepatitis B reactivation in patients receiving biological therapy
Summary: Background: The use of biologics poses a moderate to high risk for hepatitis B virus reactivation (HBVr) in chronic carriers.Aim: To determine the prevalence of HBVr with TNF alpha inhibitors, ustekinumab and vedolizumabMethod: We followed the MOOSE guidelines and conducted a comprehensive literature search. We conducted a systematic search of EMBASE (Ovid), MEDLINE (Ovid) and PubMed. The studies included patients who were chronic and occult HBV carriers with various rheumatological, dermatological or gastroenterological conditions. We used a random effects model using pooled estimates (prevalence of HBVr with 95% confidence intervals (CI)).Results: We included 29 studies with 1409 patients infected with HBV. The prevalence of HBVr in chronic carriers of HBV was 17.1% (95% CI: 7.0–35.9, n = 5), 16.6% (95% CI: 9.5–27.5%, n = 6), 40.5% (95% CI: 20.3–64.5%, n = 4) and 19.1% (95% CI: 7.3–41.2%, n = 2), respectively, for adalimumab, etanercept, infliximab and ustekinumab. The respective prevalence for reactivation in patients with occult HBV infection was 5.0% (95% CI: 2.8–8.7%, number of studies: n = 18), 2.6% (95% CI: 1.4–4.7%, n = 18), 4.4% (95% CI: 2.2–8.7%, n = 12) and 6.4% (95% CI: 2.2–16.8, n = 5). There were 39 HBVr (26 in chronic HBV and 13 in the occult group) without any hepatic failure or death. In the chronic HBVr group, only three of 24 patients received antiviral prophylaxis.Conclusions: HBVr prevalence rates differ between the chronic carrier state and the occult carrier state. The uptake of prophylactic antiviral therapy in high‐risk groups was low, contrary to clinical practice guidelines.
- 17 August 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 56 (7) , 1104-1118
Meta‐analysis: hepatitis B reactivation in patients receiving biological therapy
Summary: Background: The use of biologics poses a moderate to high risk for hepatitis B virus reactivation (HBVr) in chronic carriers.Aim: To determine the prevalence of HBVr with TNF alpha inhibitors, ustekinumab and vedolizumabMethod: We followed the MOOSE guidelines and conducted a comprehensive literature search. We conducted a systematic search of EMBASE (Ovid), MEDLINE (Ovid) and PubMed. The studies included patients who were chronic and occult HBV carriers with various rheumatological, dermatological or gastroenterological conditions. We used a random effects model using pooled estimates (prevalence of HBVr with 95% confidence intervals (CI)).Results: We included 29 studies with 1409 patients infected with HBV. The prevalence of HBVr in chronic carriers of HBV was 17.1% (95% CI: 7.0–35.9, n = 5), 16.6% (95% CI: 9.5–27.5%, n = 6), 40.5% (95% CI: 20.3–64.5%, n = 4) and 19.1% (95% CI: 7.3–41.2%, n = 2), respectively, for adalimumab, etanercept, infliximab and ustekinumab. The respective prevalence for reactivation in patients with occult HBV infection was 5.0% (95% CI: 2.8–8.7%, number of studies: n = 18), 2.6% (95% CI: 1.4–4.7%, n = 18), 4.4% (95% CI: 2.2–8.7%, n = 12) and 6.4% (95% CI: 2.2–16.8, n = 5). There were 39 HBVr (26 in chronic HBV and 13 in the occult group) without any hepatic failure or death. In the chronic HBVr group, only three of 24 patients received antiviral prophylaxis.Conclusions: HBVr prevalence rates differ between the chronic carrier state and the occult carrier state. The uptake of prophylactic antiviral therapy in high‐risk groups was low, contrary to clinical practice guidelines.
- 9 March 2022
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 21 (3) , 218-225
Primary biliary cholangitis in pregnancy: A systematic review with meta-analysis
- 9 March 2022
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 21 (3) , 218-225
Primary biliary cholangitis in pregnancy: A systematic review with meta-analysis
- Open Access
- 1 January 2022
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 28 (1) , 52-66
Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes
Background/Aims: Maternal and fetal outcomes in pregnant patients with Non-alcoholic fatty liver disease (NAFLD) have been largely unexplored. To determine the level of evidence associated with maternal and fetal outcomes in pregnant women with NAFLD.Methods: We conducted a comprehensive literature search. The studies included pregnant patients with a previous, current or subsequent diagnosis of NAFLD. We used a random-effects model using odds ratios (OR) with 95% confidence intervals (CI).Results: Twenty-two studies, with 13,641 female NAFLD patients were reviewed. The results highlight that NAFLD patients had a statistically significant increased likelihood of baseline diabetes mellitus (OR, 6.00; 95% CI, 2.21–16.31; P<0.001; n=7), baseline Hypertension (OR, 3.75; 95% CI, 2.13–6.59; P<0.001; n=4), gestational hypertension (OR, 1.83; 95% CI, 1.03–3.26; P=0.041; n=2), and pre-eclampsia (OR, 2.43; 95% CI, 1.46–4.04; P=0.001; n=3). The odds for a past and current history of gestational diabetes mellitus were OR, 3.78; 95% CI, 2.21–6.44; P<0.001; n=5 and OR, 3.23; 95% CI, 1.97– 5.31; P<0.001; n=6, respectively. As for fetal outcomes, pregnant NAFLD patients were significantly more likely to have a premature birth (OR, 2.02; 95% CI, 1.44–2.85; P<0.001; n=4), large for gestational age birth (OR, 2.01; 95% CI, 1.72–2.37; P0.05).Conclusions: This meta-analysis provides pooled evidence that NAFLD is associated with a substantial increase in maternal diabetic and hypertensive complications and multiple adverse fetal outcomes. This data is important for clinicians managing these patients before, during and after pregnancy.
- 1 January 2022
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 28 (1) , 52-66
Open AccessSystematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes
Background/Aims: Maternal and fetal outcomes in pregnant patients with Non-alcoholic fatty liver disease (NAFLD) have been largely unexplored. To determine the level of evidence associated with maternal and fetal outcomes in pregnant women with NAFLD.Methods: We conducted a comprehensive literature search. The studies included pregnant patients with a previous, current or subsequent diagnosis of NAFLD. We used a random-effects model using odds ratios (OR) with 95% confidence intervals (CI).Results: Twenty-two studies, with 13,641 female NAFLD patients were reviewed. The results highlight that NAFLD patients had a statistically significant increased likelihood of baseline diabetes mellitus (OR, 6.00; 95% CI, 2.21–16.31; P<0.001; n=7), baseline Hypertension (OR, 3.75; 95% CI, 2.13–6.59; P<0.001; n=4), gestational hypertension (OR, 1.83; 95% CI, 1.03–3.26; P=0.041; n=2), and pre-eclampsia (OR, 2.43; 95% CI, 1.46–4.04; P=0.001; n=3). The odds for a past and current history of gestational diabetes mellitus were OR, 3.78; 95% CI, 2.21–6.44; P<0.001; n=5 and OR, 3.23; 95% CI, 1.97– 5.31; P<0.001; n=6, respectively. As for fetal outcomes, pregnant NAFLD patients were significantly more likely to have a premature birth (OR, 2.02; 95% CI, 1.44–2.85; P<0.001; n=4), large for gestational age birth (OR, 2.01; 95% CI, 1.72–2.37; P0.05).Conclusions: This meta-analysis provides pooled evidence that NAFLD is associated with a substantial increase in maternal diabetic and hypertensive complications and multiple adverse fetal outcomes. This data is important for clinicians managing these patients before, during and after pregnancy.
- 15 August 2021
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 56 (10) , 1194-1204
Systematic review with meta-analysis: autoimmune hepatitis in pregnancy
Maternal and fetal outcomes in pregnant patients with autoimmune hepatitis (AIH) has been largely unexplored.This meta-analysis aims to determine the level of evidence associated with both maternal...
- 15 August 2021
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 56 (10) , 1194-1204
Systematic review with meta-analysis: autoimmune hepatitis in pregnancy
Maternal and fetal outcomes in pregnant patients with autoimmune hepatitis (AIH) has been largely unexplored.This meta-analysis aims to determine the level of evidence associated with both maternal...